Pay in 4 interest-free payments of $5.11 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
The main risks are a temporary resurgence of GI side effects (nausea, constipation, diarrhea), temporary appetite suppression reduction during the low-dose titration phase, and a short-term weight loss pause as tirzepatide builds toward therapeutic levels
IL received grant support from Merck, Mylan, Novo Nordisk, Pfizer and Sanofi, personal fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Intarcia, Janssen, Mannkind, Novo Nordisk, Sanofi, TARGETPharma and Valeritas
This study is supportive of further investigating the clinical application of GLP1 receptor agonist for HIE but also more widely for other neurological diseases
Book a free consultation
Tirzepatide is a dual GIP/GLP-1 receptor agonist, stimulating both GIP and GLP-1 pathways simultaneously
Dose calculations at 5,000 mcg/mL: 1mg dose = 0.2mL = 20 units on U-100 syringe 2mg dose = 0.4mL = 40 units 4mg dose = 0.8mL = 80 units 6mg dose = 1.2mL = 120 units 8mg dose = 1.6mL = 160 units 12mg dose = 2.4mL = 240 units This dilution makes higher doses more practical within a single syringe for mid-range protocols
US$ 27.39
US$ 27.50
US$ 29.05
US$ 29.23
US$ 21.52
US$ 27.51
US$ 22.63
US$ 24.50
US$ 21.49
